Can you recall the initial fda approval year for keytruda?

Pfizer's Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating melanoma patients whose cancer had spread to other parts of the body [1]. The FDA subsequently expanded Keytruda's approval to include additional indications, such as non-small cell lung cancer and head and neck cancer, based on new clinical trial data [2].

Keytruda is an immune checkpoint inhibitor that works by blocking the PD-1 protein on T cells, which helps to prevent cancer cells from hiding from the immune system [3]. This mechanism has led to the development of various other cancer therapies targeting the PD-1/PD-L1 axis [4].

Keytruda's approval has transformed the treatment landscape for various types of cancer, and its use has become a standard of care in many clinical settings. As of the last available data from DrugPatentWatch.com, Pfizer still holds the patent for Keytruda in the United States [5].

Sources:

[1] https://www.fda.gov/drugs/drug-approvals-and-dedications/2014-oncology-drug-applications-keytruda-pembrolizumab
[2] https://www.fda.gov/drugs/treatment-guidances/fda-approves-keytruda-pembrolizumab-treating-patients-certain-types-non-small-cell-lung-cancer
[3] https://www.mayoclinic.org/drugs-supplements/pembrolizumab/art-20465584
[4] https://www.cancer.gov/research/areas/hcsc/immunotherapy
[5] https://www.drugpatentwatch.com/patent/US10134145